|
Insights and Outcomes
Continuing Medical Education Information
Click here to download Insights and Outcomes.
Click here to take the CME test and evaluation on line
Target Audience
This activity has been designed to meet the educational needs of dermatologists, surgical oncologists, general surgeons, and medical oncologists involved in the management of melanoma.
Purpose
Present the latest research in melanoma and discuss current approaches to patient care
Educational Objectives
After completing this activity, the participant should be better able to:
- Describe the biology of melanoma development
- Describe the current AJCC staging system and areas of potential change
- Define a role for sentinel lymph node biopsy in staging melanoma patients
- Identify characteristics of patients who are appropriate candidates for adjuvant therapy
- Compare available and emerging adjuvant therapy options for melanoma
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and PharmAdura, LLC.
PIM is accredited by the ACCME to provide continuing medical education for physicians.
Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.75 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Charlotta All-Ericsson, MD, PhD
Retina & Oncology Department
St Eriks Eye Hospital Retina & Oncology Service
Stockholm, Sweden
*No financial relationships to disclose.
Andrea Anichini, PhD
Laboratory Head
Human Tumor/Immunobiology Unit
Department of Experimental Oncology
Istituto Nazionale Tumori
Milan, Italy
*No financial relationships to disclose.
Charles M. Balch, MD
Professor of Surgery and Oncology
John Hopkins Medicine
Baltimore, Maryland
*No financial relationships to disclose.
Natale Cascinelli, MD
Scientific Director
Istituto Nazionale Tumori
*No financial relationships to disclose.
Bertil E. Damato, PHD, FRCOphth
Professor of Ophthalmology
Royal Liverpool University Hospital
Liverpool, United Kingdom
*Consulting fees: NHS Ombudsman; stock ownership: Pfizer Inc; textbook royalties: Mosby, Elsevier
Reinhard Dummer, MD
Professor of Medicine
Department of Dermatology
University Hospital
Zürich, Switzerland
*No financial relationships to disclose.
Suzanne Egyházi, DMSc
Department of Oncology-Pathology
Cancer Center
Karolinska University Hospital-Solna
Stockholm, Sweden
*No financial relationships to disclose.
Tim Eisen, MD
Section of Medicine
Royal Marsden Hospital
Sutton, United Kingdom
*Consulting fees, non-CME services, contracted research, and research support: Bayer, Pfizer Inc.
David E. Elder, MB, ChB, FRCPA
Professor of Pathology
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
*No financial relationships to disclose.
Sebastian A. Eskelin, MD, PhD
Department of Ophthalmology
Helsinki University Central Hospital
Helsinki, Finland
*No financial relationships to disclose.
Keith T. Flaherty, MD
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
*Consulting fees: Bayer/Onyx, Chiron Inc, Plexxicon, Inc.
Helen J. Gogas, MD
Assistant Professor in Medical Oncology
First Department of Medicine
University of Athens Medical School
Athens, Greece
*Consulting fees: Schering-Plough Corporation.
Jean-Jacques Grob, MD
Hôpital Sainte Marguerite
Marseille, France
*No financial relationships to disclose.
Johan Hansson, MD PhD
Associate Professor
Department of Oncology-Pathology
Karolinska Institutet
Stockholm, Sweden
*No financial relationships to disclose.
Axel Hauschild, MD
Professor of Dermatology
Department of Dermatology, Campus Kiel
University Hospital
Kiel, Germany
*Consulting fees, contracted research: Schering-Plough Corporation.
Meenhard Herlyn, DVM, DSc
The Wistar Institute
Philadelphia, Pennsylvania
*No financial relationships to disclose.
Peter Hersey, FRACP, DPhil
Professor in Oncology
University of Newcastle
Newcastle, Australia
*No financial relationships to disclose.
Ulrich Keilholz, MD
Professor of Medicine
The Free University of Berlin
Berlin, Germany
*No financial relationships to disclose.
John M. Kirkwood, MD
Director, Melanoma and Skin Cancer Program
University of Pittsburgh Cancer Institute
Professor and Vice Chairman for Clinical Research
Department of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
*Grants/Research Support: Schering-Plough Corporation, Berlex Laboratories, Pfizer Inc; Consultant: Antigenics Inc, MedImmune, Inc; Speakers' Bureau: Schering-Plough Corporation.
Sewa Legha, MD
Melanoma Center at the Texas Cancer Institute
St Luke's Episcopal Hospital
Houston, Texas
*Non-CME services: Schering-Plough Corporation.
Helena Linardou, MD, PhD
Assistant Director
Department of Medical Oncology
Metropolitan Hospital
N Faliro, Athens, Greece
*No financial relationships to disclose.
Rona M. MacKie, MD, DSc
Department of Public Health and Health Policy
Glasgow University
Glasgow, United Kingdom
*No financial relationships to disclose.
Richard Marais, PhD
CRC Centre for Cell and Molecular Biology
Institute of Cancer Research
London, United Kingdom
*No financial relationships to disclose.
Geoffrey P. Margison, PhD
Cancer Research UK Carcinogenesis Group
Paterson Institute for Cancer Research
University of Manchester
Manchester, United Kingdom
*No financial relationships to disclose.
Mark Middleton, PhD
Cancer Research UK
Medical Oncology Unit
Churchill Hospital
Oxford, United Kingdom
*Consulting fees: AstraZeneca, MedImmune, Inc; contracted research: GlaxoSmithKline, Schering-Plough Corporation; Other: Schering-Plough Corporation.
Giorgio Parmiani, MD
Istituto Nazionale Tumori
Milan, Italy
*No financial relationships to disclose.
Jacob Pe'er, MD
Professor and Chairman
Department of Ophthalmology
Hadassah Hebrew University Medical Center
Jerusalem, Israel
*No financial relationships to disclose.
Peter Riegman, PhD
Erasmus Medical Center
Rotterdam, The Netherlands
*No financial relationships to disclose.
Ulrik Ringborg, MD, PhD
Professor
Karolinska Institute
Stockholm, Sweden
*No financial relationships to disclose.
Merrick I. Ross, MD
Professor of Surgical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas
*Speakers' Bureaus: Schering-Plough Corporation, Genentech, Inc.
Alain Spatz, MD
Department of Pathology
Institut Gustave-Roussy
Villejuif, France
*No financial relationships to disclose.
Lynn E. Spitler, MD
Director, Northern California Melanoma Center
Saint Francis Memorial Hospital
San Francisco, California
*No financial relationships to disclose.
Alessandro Testori, MD
Melanoma Unit
Istituto Europeo di Oncologia
Milan, Italy
*No financial relationships to disclose.
J. Meirion Thomas, MS, FRCP, FRCS
Royal Marsden Hospital
London, UK
*No financial relationships to disclose.
Mathias Uhlén, PhD
School of Biotechnology
Royal Institute of Technology
Stockholm, Sweden
*No financial relationships to disclose.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lisa A. Faltyn, PhD
Managing Partner
PharmAdura, LLC
*No conflicts of interest with any commercial entity.
Mike L. Coco, PhD
Medical Writer
*No conflicts of interest with any commercial entity.
Linda Graham, RN, BSN, MSN
Postgraduate Institute of
Medicine
*No conflicts of interest with any commercial entity.
Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period September 2006 through October 2007 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within three weeks.
Media
Monograph
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), PharmAdura, LLC, and Schering-Plough Corporation do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, PharmAdura, LLC, and Schering- Plough Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Release date: November, 2006
Expiration date: November 20, 2007
Estimated time to complete activity: 1.75 hours
| 
